NYSEIndustrialsMedical - Care FacilitiesSnapshot 2026-08-31
Reading GMRS? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Industrials is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
No standing thesis yet — not enough to read.
View ThesisExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 24% in its worst 12-month stretch.
View RiskGMRS's growth has to keep compounding to justify the price. Revenue grew 3% year over year, but the latest quarter missed expectations. GMRS trades at a low-confidence valuation, with no clean multiple available. The price reflects less growth than forecast, suggesting modest expectations. If GMRS cuts guidance on the next call, that could negatively impact the stock. Peer multiples imply a price about 37% above where it trades. Our standing thesis is forming; there is not enough to read.
Trailing returns as of 2026-08-31. GMRS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering GMRS (as of Aug 2026).
Based on 6 Wall Street analysts offering 12-month price targets for GMRS in the last 4 months.
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-08-31. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Facilities — fair value, gap to price, and forward P/E.
New board members enhance leadership and strategic direction.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-08-31. EPS is implied from price ÷ P/E. Not investment advice.
Current $12.15
The last 12 months of price, then the range of analyst 12-month targets from today’s $12.15.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
New board members enhance leadership and strategic direction.
